Los Angeles Biotechnology Network
  • Home
  • About
  • News
    • All LABN News
    • Trending LABN News
  • Jobs
    • All LABN Jobs
    • Post A Job
  • Subscribe
  • Contact
News Ticker
  • [ November 30, 2022 ] Postdoctoral Fellow – CAR T Cell Therapy – City of Hope – Duarte, CA Los Angeles Biotech Jobs
  • [ November 30, 2022 ] Research Associate I – Cancer and Stem Cell Biology – City of Hope – Duarte, CA Los Angeles Biotech Jobs
  • [ November 30, 2022 ] Arcadia Biosciences (RKDA) Announces CFO Transition Los Angeles Biotech News
  • [ November 30, 2022 ] Security Officer – Biotech Company – Allied Universal® – Oceanside, CA Los Angeles Biotech Jobs
  • [ November 30, 2022 ] SkillsetGroup CEO in Inc. Magazine: Keep Your Employee; Give them a Path Los Angeles Biotech News
HomeLos Angeles Biotech NewsSTAT Plus: Study of experimental heart drug from Cytokinetics, Amgen meets goal — but still disappoints

STAT Plus: Study of experimental heart drug from Cytokinetics, Amgen meets goal — but still disappoints

October 8, 2020 Los Angeles Biotechnology Network News Los Angeles Biotech News Comments Off on STAT Plus: Study of experimental heart drug from Cytokinetics, Amgen meets goal — but still disappoints
Cytokinetics and Amgen said their study of an experimental heart drug achieved its main goal, but the treatment effect was marginal.

Click to view original post

Previous

New Preclinical Study Finds Nicotinamide Riboside May Improve Immune Cell Function

Next

Takeda drops $300M cash to kick off $1B RNAi alliance with Arrowhead, shooting for first-in-class rare disease drug

Follow/Subscribe

POST A JOB
Tweets by LABioNetwork

Copyright © 2021 Biotech Networks, LLC

Want to Save Time?

Get Trending News & Jobs Delivered